Trending

Early Access to Medicines Scheme

Merck’s targeted lung cancer drug tepotinib wins early access in UK

Merck’s targeted lung cancer drug tepotinib wins early access in UK

The UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small

X

Merck’s targeted lung cancer drug tepotinib wins early access in UK

https://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/

BI drug named Promising Innovative Medicine in mesothelioma

BI drug named Promising Innovative Medicine in mesothelioma

Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for

X

BI drug named Promising Innovative Medicine in mesothelioma

https://pharmaphorum.com/news/bi-drug-named-promising-innovative-medicine-mesothelioma/

UK patients gain early access to Duchenne drug

UK patients gain early access to Duchenne drug

Patients to get Santhera’s Raxone under EAMS scheme.

X

UK patients gain early access to Duchenne drug

https://pharmaphorum.com/news/uk-patients-get-early-access-duchenne-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com